Drug intelligence / Profile preview

AK1320

Development stage: Phase 1
Lead developer: Asahi Kasei
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Local Administration, Surgical Implantation

Overview

AK1320 is a drug developed by Asahi Kasei Pharma Corporation. Its microsphere formulation, AK1320 MS, is currently undergoing a first-in-human study to evaluate its safety and efficacy in patients with degenerative spondylolisthesis and concomitant symptomatic spinal stenosis who are undergoing decompression and single-level instrumented posterolateral lumbar autograft fusion surgery. The specific mechanism of action for AK1320 has not been disclosed in the provided information.

Other names: AK1320 Encapsulated MicrospheresAK-1320 Encapsulated MicrospheresAK 1320 Encapsulated MicrospheresAK-1320-MSAK1320-MSAK 1320-MS

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)

Beyond the preview

Go deeper on AK1320.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK1320.

Explore the full profile